FDA-Approved Pill Cracks Cancer’s Fortress

A close-up view of a variety of colorful pills and tablets stacked together

A rare liver cancer that strikes mostly young adults has found a way to hide from the immune system — and researchers just found a key to unlock the door.

Story Snapshot

Fibrolamellar carcinoma traps immune cells at the edge of tumors, keeping them from doing their job.
A Cornell University study found that an existing FDA-approved drug called AMD3100 breaks that trap and lets immune cells flood into the tumor core.
When AMD3100 was combined with immunotherapy, tumor cell death jumped significantly in lab tests using real patient tumor slices.
No human clinical trials have started yet, but the drug’s existing approval could speed up that process considerably.

A Rare Cancer With Almost No Good Options

Fibrolamellar carcinoma is a rare and deadly liver cancer. It mostly hits teenagers and young adults who have no history of liver disease. That makes it especially cruel. Standard liver cancer treatments barely work on it. Immunotherapy — the approach that teaches your own immune system to kill cancer — has shown only modest results. The largest study on immunotherapy for this cancer found just a 15.8% response rate among patients. ^[4] Most patients get little to no benefit.

The reason immunotherapy struggles here turns out to be a specific biological trick the tumor plays. Fibrolamellar tumors send out chemical signals that pull T cells — the immune system’s attack soldiers — toward the tumor but then trap them at the outer edge. The T cells never get inside where the cancer cells live. They are essentially locked out. Cornell University researchers published this finding on February 17, 2026, in the journal Gastroenterology, and it changes how scientists think about treating this disease. ^[1]

How AMD3100 Breaks the Tumor’s Defense

AMD3100 is already approved by the U.S. Food and Drug Administration (FDA) for a different condition — it helps patients mobilize stem cells before bone marrow transplants. The Cornell team found it also blocks the chemical signal fibrolamellar tumors use to trap T cells. When researchers applied AMD3100 to actual patient tumor slices, T cells moved into the tumor core. That had not happened before. ^[1] Combine AMD3100 with standard immunotherapy checkpoint drugs, and tumor cell death increased significantly in those same tissue tests.

Praveen Sethupathy, the Cornell researcher who led the study, put it plainly: “A compelling feature of this work is that AMD3100 is already FDA-approved, which can reduce risks and potentially speed up timelines for clinical trials in fibrolamellar carcinoma.” ^[1] That matters enormously for a disease this rare. Getting a brand-new drug approved from scratch can take a decade. Starting with a drug that already has a safety record cuts that timeline down. The team also worked with researchers at the University of Washington who tested the drug on patient tumor slices, adding real-world tissue evidence to the lab findings.

Promising Lab Results Do Not Equal a Cure Yet

Here is where honest reporting requires a pause. No human patients have been treated with this combination yet. The evidence comes from tumor slices in a lab setting, not from people walking into a clinic and getting better. The Cornell team is currently searching for liver cancer doctors willing to start clinical trials. ^[1] That search has not concluded. There is no Phase I trial data, no survival numbers, and no safety profile for combining AMD3100 with checkpoint drugs specifically in this cancer. The excitement is real, but it is early-stage excitement.

This kind of drug repurposing story follows a well-worn path in cancer research. The average time between a drug’s first approval and its successful repurposing for a new disease is about 7.2 years — still faster than building a new drug from nothing. ^[13] Thalidomide went from morning sickness drug to a cornerstone treatment for multiple myeloma. Metformin, a diabetes drug, is now in cancer trials worldwide. AMD3100 joining that list is plausible. But plausible is not proven. Researchers still need to find which patients will respond best, confirm the safety profile in combination therapy, and measure whether survival actually improves.

Why This Still Deserves Serious Attention

Fibrolamellar carcinoma is so rare that the largest clinical study of immunotherapy in these patients included only 19 people. ^[4] Recruiting enough patients for a statistically solid trial is genuinely hard. That scarcity also means pharmaceutical companies have little financial incentive to invest heavily. The FDA is actively seeking ideas for repurposing approved drugs to address rare diseases with unmet needs, which creates a real regulatory opening for exactly this kind of research. ^[16] The mechanism Cornell identified is clear, the drug is already approved, and the patient tissue results are encouraging. Those three facts together make this worth watching closely — just not worth celebrating prematurely.